Table 1. Clinical characteristics of enrolled subjects in the study.
| Group | HC | IT | IA | IC | RP |
|---|---|---|---|---|---|
| Case | 22 | 12 | 32 | 11 | 13 |
| Sex (male/female) | 11/11 | 11/1 | 30/2 | 9/2 | 12/1 |
| Age (years) | 28 (24–35) | 29 (16–60) | 34 (15–63) | 44(19–62) | 37 (22–53) |
| HBsAg/HBsAb | −/+ | +/− | +/− | +/− | −/+ |
| HBeAg/HBeAb | −/− | +/− | +/− | −/+ | −/− |
| ALT (U/L) | ND | 23 (13–37) | 292 (54–1885) | 28 (5–40) | 28 (15–45) |
| AST (U/L) | ND | 23 (16–32) | 128 (27–875) | 19 (6–38) | 19 (12–38) |
| HBV DNA (100 IU/ml) | ND | 8.2 (7.8–8.9) | 6.8 (3.3–8.8) | LDL | LDL |
Abbreviations: HC, healthy controls; IA, Immune activation; IC, immune clearance; IT, Immune tolerance; LDL, lower detection limitation; ND, not determined; RP, responders with HBsAg seroconversion.
Data are shown as median and range.